Articles tagged with Vaccine Development
Researchers developed a new protein-based vaccine candidate that successfully inhibited pneumococcus from establishing a foothold in the body, providing near-complete protection. The vaccine stimulates TH17 cells, which provide natural immunity to pneumococcal infection.
The Dengue Vaccine Initiative aims to accelerate the development and utilization of safe, affordable, and broadly protective vaccines to combat dengue fever. The initiative will generate data on the burden of disease, potential private demand, cost of illness, and seroprevalence in several countries.
A new study has identified a potential vaccine that targets H. pylori bacteria, which causes gastritis, ulcer disease, and gastric cancer. The vaccine was found to be more effective when delivered intranasally.
Researchers combined two proteins and a stress response protein to create a new TB vaccine strategy that provided stronger, more long-lasting protection than the current BCG vaccine. The study found that this multistage vaccine controlled reactivation of latent infection and reduced Mtb levels in the lungs more effectively.
Scientists have made a breakthrough in developing a vaccine to protect against plague and bacterial pneumonias. The new discovery involves the stimulation of Th1-17 cells, which provide partial protection against pneumonic plague.
The MSD Wellcome Trust Hilleman Laboratories is conducting a feasibility study to develop a rotavirus vaccine designed specifically for developing country needs. The project aims to improve product stability, ease of use, transportation, and affordability.
New findings reveal that broadly-reactive neutralizing antibodies (bNAbs) develop earlier than previously thought, in some cases as soon as a year after infection. These antibodies target only a few regions of HIV, making it easier to design new immunogens and protocols for vaccine development.
A new study confirms that two doses of the varicella, or chickenpox, vaccine provide excellent protection in children against this highly contagious and, in some cases, severe disease. The study found that the effectiveness of two doses of vaccine was 98.3 percent in protecting against varicella, significantly higher than one dose.
A new type of vaccine is being developed that can trick the body into developing immunity against polio, with no risk of causing or spreading the disease. The replica virus particle will be designed to look and behave like the real virus but contain no genetic material.
Researchers discovered the FMD virus selectively infects epithelial cells in the nasopharynx after just six hours of exposure. This breakthrough could lead to the development of more effective vaccines and potentially eradicate the disease, which causes significant economic losses globally.
A new dry powder HPV vaccine offers improved effectiveness and lower costs by targeting mucous membranes directly, reducing contamination risks. This innovative delivery method aims to expand HPV vaccination access to more people globally, particularly in developing countries.
The NIH has awarded a five-year grant to develop a painless, self-administered flu vaccine using patches containing tiny microneedles. The technology aims to improve vaccination rates, especially among children and the elderly, by reducing the need for medical personnel.
The Aeras Global TB Vaccine Foundation has received an additional €11.7 million grant from the Netherlands Ministry of Foreign Affairs to develop new vaccines against tuberculosis.
Scientists have discovered that pneumolysin triggers an immune response by activating the NLRP3 inflammasome, which provides protection against infection caused by Streptococcus pneumoniae. This breakthrough could lead to more effective vaccines for pneumococcal diseases.
USDA scientists have developed vaccines to protect farm-raised catfish against key diseases, including Streptococcus iniae and S. agalactiae. The modified live vaccine has been shown to create a lifelong immunity in fish, with previous research breakthroughs benefiting the catfish industry.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded contracts to develop three biodefense vaccines to protect against dengue, anthrax, and other emerging infectious diseases. The vaccines aim to improve vaccine delivery and immune response for large-scale protection.
The Aeras Global TB Vaccine Foundation has received a $362,102 grant from the US FDA to develop new biological and immunological biomarkers for TB vaccine development. The project aims to evaluate four mycobacterial growth inhibition assays and identify T-cell immune responses associated with protective vaccines.
A new TB vaccine candidate called AERAS-422 is undergoing clinical trials to evaluate its safety and immunogenicity. The vaccine aims to interrupt TB at all stages of infection, including initial infection, latency, and reactivation.
The Phase II study will establish the optimal dosing regimen and then be tested in Kenya, Mozambique, South Africa, and Uganda. The TB vaccine candidate has been shown to have an acceptable safety profile in early-stage clinical trials.
The formation of AVAN, the AIDS Vaccine for Asia Network, aims to accelerate research and development of an AIDS vaccine through government advocacy and improved coordination. With over 5 million people infected and 500 million at risk, regional efforts must be strengthened to combat HIV in Asia.
A new hepatitis E vaccine has demonstrated 100% efficacy in preventing infection, with protection offered across all age and sex subgroups. The vaccine is safe and can be used in both rich and poor countries, as well as for tourists, making it a crucial development in outbreak control.
A South Korean study has shown that patients infected with hepatitis B are around twice as likely to develop non-Hodgkin lymphoma. The study found an increased risk of NHL and malignant immunoproliferation in HBV-positive individuals.
Researchers at University of Miami use computer algorithms to design live vaccines, which are then synthesized to specification. This approach allows for a wide margin of safety against potential mutations, enabling the creation of safe and effective vaccines against various types of viruses.
Researchers found that HPV vaccines are not covered by patent claims granted in India, leaving room for production of biosimilars offering protection against the two most common HPV strains. This could improve access to the HPV vaccine in low-income countries.
Experimental vaccines developed with these approaches produced strong immune responses in mice, potentially safer than the only available RVF vaccine. Researchers are hopeful that these new strategies may be advantageous to controlling RVF, providing a safer alternative to existing live virus vaccines.
Researchers at Mount Sinai School of Medicine have developed a new influenza vaccine that targets the HA globular head, bringing science closer to a universal influenza vaccine. The vaccine was shown to be effective against multiple strains in mice, with all vaccinated mice surviving and unvaccinated mice dying.
A newly developed experimental Ebola vaccine has shown protection in monkeys against a newer Ebola virus species identified in 2007. The vaccine induces a robust T-cell response that can cross-react with other Ebola virus species.
Researchers have developed a novel influenza vaccine that could represent the next step towards a universal influenza vaccine eliminating seasonal immunizations. The vaccine uses headless hemaglutinin (HA) protein, inducing a broader and more robust immune response in mice.
Experts argue for shifting focus from biomedical mechanisms to socio-environmental aspects of neglected tropical diseases. Mass drug administration is recognized as a cost-effective approach for controlling these diseases, while integrating biomedical and social approaches through 'social offsets' may complement this strategy.
Scientists have developed an immune-deficient mouse model to study CCHF virus behavior in humans, a significant step towards vaccine and antiviral development. The model can help evaluate the safety and effectiveness of potential treatments, addressing the lack of suitable animal models for testing.
A study found that south-south collaborations between biotech firms in developing countries are increasing, enabling the production of affordable health products. These collaborations have already led to successful vaccine development and distribution, such as the Brazil-Cuba collaboration during Africa's meningitis outbreak.
The dry powder, inhalable vaccine has been shown to be stable under challenging environmental conditions and is estimated to cost only 26 cents per dose. Phase One clinical trials are set to start in India this summer, followed by Phase Two trials involving a larger number of patients.
A new HIV modeling system developed by Chinese researchers suggests that CD8+ T cells could be useful in developing an AIDS vaccine. The model incorporates random patterns in the virus' mutation and immune response, mirroring real-life clinical behavior.
Researchers have developed a new vaccine strategy using the Giardia parasite's surface proteins to prevent or mitigate future infections. The engineered parasites work as effective vaccines when given orally to gerbils, offering a promising approach for delivering oral vaccinations in developing countries.
The Lancet Editorial calls for increased public commitment to combat malaria, citing a 20-year development timeline and £500 million investment. A broader public-private partnership is needed to support the development of an effective vaccine, with $20 billion pledged by Bill Gates.
A new study by the University of Edinburgh found that respiratory syncytial virus (RSV) claims the lives of up to 200,000 children globally each year. The research also showed that about 3.4 million children require hospital treatment for severe lung infection caused by RSV.
Researchers developed a vaccine targeting an abnormal protein MUC1, found in both IBD and colon cancer. The vaccine delayed IBD development and reduced inflammation, reducing cancer risk.
Researchers have developed an experimental vaccine for chikungunya virus, which has already infected millions of people in Asia, Africa, and Europe. The vaccine, composed of virus-like particles, successfully protected monkeys from infection.
The American Society for Microbiology honors Samuel L. Katz with the Maurice Hilleman/Merck Award for his decades-long work on vaccine development. Katz, a renowned expert in vaccine research, has made significant contributions to pathogenesis, vaccine discovery, and disease prevention.
A research program aimed at understanding malaria infection and developing effective treatments and vaccines has been awarded $12.7 million. The program will investigate the parasite's ability to evade the immune system and develop resistance to existing drugs.
Scientists have developed a simple and cheap way to make vaccines stable at tropical temperatures, eliminating the need for refrigeration. The method involves mixing vaccines with sugars and drying them on membranes, preserving the active part of the vaccine and allowing it to be shipped at normal temperatures.
Scientists at Oxford University have developed a new method to make vaccines stable at tropical temperatures using Nova Bio-Pharma Technologies' patented HydRIS system. This technology has the potential to revolutionize vaccination efforts, particularly in the developing world where infectious diseases kill millions of people every year.
Researchers developed peptide vaccines that stimulate T cells to attack cancer cells in mice, achieving 100% tumor-free survival for at least 60 days. The successful vaccines stimulated T cells recognizing both the peptide vaccine and natural antigens, producing a large population of activated T cells.
Researchers have proven that subneutralizing levels of dengue virus antibodies exacerbate the disease, contradicting the normal function of antibodies. This finding has major implications for developing a vaccine against dengue virus, which annually infects 50-100 million people worldwide.
Researchers have developed a new malaria vaccine that has shown strong and long-lasting immune responses in young children, surpassing antibody levels found in adults. The vaccine, FMP2.1/AS02A, targets the blood stage of the disease and was tested in 100 Malian children, with all doses proving safe and well-tolerated.
Pneumococcal disease is a leading vaccine-preventable killer of children under age five, causing life-threatening infections. Dr. Thomas Cherian's work has helped advance medical science and inform policy to overcome obstacles in awareness, financing, and vaccine access.
Scientists have developed an experimental VLP vaccine that protects macaques and mice against chikungunya virus, a debilitating disease with no current treatment. The vaccine, using non-infectious virus-like particles, elicits immune responses and provides complete protection from infection.
The rotavirus vaccine has been shown to prevent severe diarrhoea in African children, with a 61.2% reduction in incidence. The vaccine's efficacy was lower in Malawi compared to South Africa, but it still demonstrated significant impact in reducing mortality rates.
Researchers at Uppsala University have identified a biodegradable substance with higher activity than existing adjuvants, paving the way for therapeutic vaccines to be used as cost-effective treatments for diseases like cancer and allergies.
The HPV-16/18 AS04-adjuvanted vaccine (Cervarix) induces a strong and sustained antibody response and has a favourable safety profile. Vaccine efficacy against incident infection with HPV-16/18 was 95% and against 12-month persistent infection was 100%.
The Elsevier journal Vaccine has released a supplement dedicated to vaccines for biodefense, showcasing significant advancements in vaccine development against diverse human and veterinary pathogens. The publication acknowledges the shift from traditional military focus to protecting both civilian and military populations.
The National Institute of Allergy and Infectious Diseases has awarded approximately $208 million to two programs that support research on the human immune response to emerging and re-emerging infectious diseases. This funding aims to identify new vaccines and drug targets, with a focus on developing prevention tools and therapeutics.
Researchers identified 78 homegrown health biotechnology companies producing innovative products for all neglected diseases, including the Big 3. A proposed 'Global Health Accellerator' service aims to connect these firms with expertise and funding to reach additional villages worldwide.
The Walter and Eliza Hall Institute has received a US$100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation to develop a genetically attenuated live malaria vaccine. The project aims to provide strong and lasting immunity against Plasmodium falciparum, the parasite that causes deadly human malaria.
A systematic review of six randomized trials found pneumococcal conjugate vaccines reduced vaccine-type IPD by 80%, all-serotype IPD by 58% and x-ray defined pneumonia by 27%. The vaccines also prevented 11% of child deaths.
A study published in Virology demonstrates that the ancient pathogen cowpox still has much to teach us about developing novel vaccines. Researchers identified 9 new protective components of the virus, which offered superior protection in a mouse model compared to existing vaccines.
The Government of Canada is supporting scientific research to deepen knowledge of the H1N1 flu virus. Five new projects, totaling $2.4 million over two years, will investigate how to manage health-care resources during a pandemic, impact on pregnant women, and development of new drug therapies.
A new method of delivering measles vaccines, using an inhalable powder, has shown promise in test animals. The powder is produced by mixing a weakened measles virus with high-pressure carbon dioxide and can remain stable for at least eight weeks at room temperature.
The MSD Wellcome Trust Hilleman Laboratories aims to develop new vaccines to prevent diseases affecting low-income countries. The not-for-profit joint venture will work on optimizing existing vaccines and developing new ones, with the goal of increasing vaccine impact in resource-limited settings.
Researchers at Oregon State University have developed a new vaccine adjuvant using lecithin nanoparticles, which showed improved immune response and reduced toxicity compared to existing alum-based adjuvants. The new adjuvant could potentially become a universal carrier for vaccines and help tackle various diseases more effectively.